GlassScriptPhysician profile
Christopher C Robinson
NPI 1952558892
$2,609.08
in general payments reported to CMS, 2019-2025
26 companies · $729 in 2025
The $729 reported for 2025 was more than what 86% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.74 · 2022: $587 · 2023: $797 · 2024: $446 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Travel and Lodging: $863 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.24 |
| Travel and Lodging | $862.79 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,096.43 | 2022-2023 | Interstim |
| Smith+Nephew, INC. | $418.84 | 2025 | Evos |
| Idorsia Pharmaceuticals US INC | $123.52 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $122.90 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $113.48 | 2024 | Epclusa |
| Neurelis, INC. | $111.57 | 2024 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.47 | 2022 | |
| Sumitomo Pharma America, INC. | $76.62 | 2024-2025 | Gemtesa, Orgovyx |
| Antares Pharma, INC. | $53.82 | 2024-2025 | Xyosted |
| Ferring Pharmaceuticals INC. | $50.23 | 2025 | Adstiladrin |
| Janssen Biotech, INC. | $43.90 | 2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $43.58 | 2022 | |
| Boston Scientific Corporation | $27.62 | 2025 | Advantage System |
| Merck Sharp & Dohme LLC | $24.97 | 2023 | Keytruda |
| Verity Pharmaceuticals INC. | $24.56 | 2025 | Trelstar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sagent Pharmaceuticals | $22.23 | 2025 | Glydo |
| Clarus Therapeutics INC. | $22.23 | 2021 | |
| Polynovo North America LLC | $22.14 | 2024 | Novosorb Btm |
| Teleflex LLC | $21.74 | 2025 | Urolift |
| Endo USA, INC. | $17.91 | 2025 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $17.23 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $17.08 | 2022 | |
| Solventum Corporation | $15.85 | 2024 | Activ.A.C. |
| Merit Medical Systems INC | $14.65 | 2024 | Savi Scout |
| Hollister Incorporated | $14.12 | 2021 | |
| Braintree Laboratories, INC. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.